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Abstract
Background: Fibrinogen (FIB) is an important source of fibrin, which plays a crucial role in circulating tumor cells
(CTCs) extravasation and distant metastasis development. We hypothesize it’s stable final product, plasma D-dimer,
may be associated with CTCs appearance and can reflect the metastatic phenotype in cancer patients.
Methods: We first verified our hypothesis in different murine gastric cancer metastasis models in vivo, plasma D-dimer
and fibrinogen as well as its degradation products were directly examined in three metastasis immune-deficient mouse
models and in controls. Next, we gathered and analyzed the result of plasma D-dimer levels and CTCs numbers in 41
advanced primary gastric cancer (GC) patients. A follow-up study was conducted in these patients.
Results: In three in vivo murine metastasis models, plasma D-dimer levels were extremely elevated in a hematogenous
and intraperitoneal murine model of metastasis compared with a subcutaneous tumor model and the control group,
supporting our previous hypothesis. While in 41 GC patients, the result displayed that plasma D-dimer levels were
remarkably increased in patients with distant metastases, especially in visceral metastases patients. Additionally, linear
association was shown between D-dimer level and CTCs numbers (R2 = 0.688, p < 0.001), additionally, plasma D-dimer
represent a better survival predictor than CTCs.
Conclusions: Plasma D-dimer is an essential accompaniment of CTCs in GC that is easy to measure and lower in cost,
and can be used in the detection of hematogenous metastasis.
Keywords: D-dimer, Gastric cancer (GC), Metastasis, Circulating tumor cells (CTCs), Outcome
Background
Metastasis is beginning when primary tumor release
tumor cells into circulatory system becoming CTCs [1].
After CTCs arrest and generated in vascular, they must
working together with coagulant factors like platelets
(PLT), FIB and other clotted plasma factors to form
micro-thrombus to help them to adhere and transfer in
distant organs [2]. Based on previous studies, they believe
there was a close relationship between higher tumor-
associated procoagulant activity state and tumor metasta-
sis [2, 3]. Coagulation and fibrinolysis system activation in
cancer patients, may partly reflects the diffusion of tumor
cells in host circulatory system.
Fibrinogen (FIB) is an important source of fibrin,
which plays a crucial role in circulating tumor cells
(CTCs) extravasation and distant metastasis develop-
ment [4, 5]. D-dimer, the final stable product of fibrin,
which elevated after enhanced activation of Coagulation
and fibrinolysis system, widely used in detect and
exclude deep vein thrombosis and associated thrombo-
embolic diseases [6–8]. Recent years, several studies
reported that plasma D-dimer elevated in malignant tu-
mors and its expression levels positively correlates with
an advanced tumor stage, overall survival and therapy
response [9–16]. In our previous study in GC patients,
we found, D-dimer can better predict asymptomatic
visceral metastasis than FIB and other factors [16].
Although FIB is essential in CTCs survival, but not
strong in clinical use to detect metastasis, but D-dimer
revealed its advantages in this field. It may be associated
with CTCs appearance and can reflect the metastatic
phenotype of caner patients.
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The overall survival in advanced tumor stage in GC
patients is not so optimistic in present study of the
word, so early diagnose of metastasis is an important
step in GC patients. We designed this multiple experi-
mental study based on previous research to found If it is
a reflector when CTC arise in circulation and the direct
association of circulating tumor cells and D-dimer, we
also want to explore the effectiveness of the manage-
ment of metastasis by plasma D-dimer and compared
with other factors like CellSearch system detected
CTCs in GC patients. In this study, we first verified our
hypothesis in different murine models in vivo. We also
tested the in vivo levels of fibrinogen (FIB) and fibrin
degradation products (FDP). Then, we collected data
from blood samples of advanced GC patients to evalu-
ate the clinical use of D-dimer in the detection of
hematogenous metastasis and to determine the correl-
ation with CTCs. CTC counts in this study were detected
by the CellSearch system with specific antibodies, CTC
cells was detected with CK (cytokeratins8, 18, and/ or 19)
(+) and DAPI(+) and CD45(−).
Methods
Cell culture
The human GC cell lines (MGC80-3 (TCHu 84), AGS
(TCHu232)) obtained from Type Culture Collection of
Shanghai Chinese Academy of Sciences which conserved
in our lab, the cells were cultured in mediem (DMEM,
Hyclone, Logan, UT, USA) supplemented with fetal calf
serum (10% concentration, Hyclone, Logan, UT, USA).
Animal experiments
To better understand the relationship between plasma D-
dimer levels and the progression of human GC, we
injected human GC-derived cells into immune-deficient
mice; The male immune-deficient mice purchased from
Beijing Laboratory Animal Center, 5 × 105 GC cells (AGS
and MGC80-3) were separated and injected into the mice
subcutaneously to induce subcutaneous metastasis, into
the abdominal cavity to induce intra-peritoneal metastasis,
and into mice tail vein to induce hematogenous metas-
tasis, respectively. The control mice were injected with
200 μl of PBS. After 2 weeks, murine blood was harvest
from the eyeball and placed in the tube with heparin
lithium-anticoagulant. At the same time, we also per-
formed dissections of these mice and the lungs were re-
moved to detect hematogenous metastasis.
Patients
GC patients diagnosed by a pathologist according to an
endoscopic biopsy and who were hospitalized at the First-
Affiliated-Hospital of medicine collage, Xi’an Jiaotong
University between 1st Jan 2009 and 1st Jan 2013 were
enrolled in this study. Anyone who had history of venous
thrombosis or received any anti-coagulation treatment
was excluded. Also excluding principle involved cerebro-
vascular or cardiovascular disease, inflammatory diseases,
history of malignancies, and those who received previous
anticancer treatments were also excluded. After exclusion
of the above-mentioned patients, a total of 41 GC patients
were involved in our study, Of which all the patients re-
ceived similar chemotherapy treatment. (5-fluorouracil,5-
Fu, oxaliplatin, OXA and folinic acid, 4–8 times; at the
interval of 2 weeks) after nearly 3 weeks recovery of sur-
gery, except one patients only receive 2 times before dead
and the overall survival is 2 month. 29 patients received
treatment in First Affiliated Hospital of medicine college
of Xi’an Jiaotong University accepted continues follow-up
by telephone or in hospital. All the follow-up terminated
in Jan 2015 as defined >2 year. There were two additional
end-point referring to tumor recurrence and pass away.
Cancer stage was defined in the accordance of American
Joint Committee on Cancer-7 (AJCC-7).
D-dimer assays
Venous blood was collected in sodium citrate tubes from
each sample for D-dimer detecting. The amount of FDP,
FIB, D-dimer and CEA were assayed using ELISA detec-
tion. In clinical detection, latex-enhanced immunoturbi-
dimetric assay was also used to analysis the level of FIB.
FDP and D-dimer, which were the same as our previous
experiment [15], all the samples were collected when
they first get pathological diagnosis before any treatments.
D-dimer level in normal human plasma is usually below
1.0 μg/ml.
CTC counts
Following the instruction of CellSearch system (Veridex
LLC, Warren, NJ, USA), blood CTCs were isolated by
immunomagnetic, and then, immune-fluoresence-staining
was employed to detected CTCs positive cells in the
mechanism that CTCs were identified by lacking CD45
which express cytokeratin (8, 18, and/ or 19). The method
and criteria of defining tumor cell was the same with
instructed previously [17]. 7.5 ml of blood of each patient
enrolled was accumulated to detect CTCs, and the detail
of CellSpotter & CellSearch was all discussed by Allard, et
all [17]. As previous reported, 2 CTCs or more detected in
7.5 ml blood is defined as CTCs positive [17]. Based on
this criterion, more than 2 CTCs in one blood sample was
defined as positive in this study.
Statistical analysis
All the data was analyzed using analysis software SPSS
13.0 (IL, USA). The data from in vivo was present in the
form of SE, that is mean ± standard error, two-tailed
Students’ T-test and multiple comparison in ANOV
were used. For distribution of plasma D-dimer in GC
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patient was not in normal way, so quartile range (Q) and
median (M) were used to report it. Also, Spearman
correlation analysis was used to evaluate univariate
analysis. In order to identify any independent variables
about D-dimer, multiple linear regression models also
was selected. Survival were analyzed by log-rank tests,
and survival curves was formed in the help of Kaplan-
Meier method The statistically significant was defined
as p < 0.05.
Result
Plasma D-dimer in vivo model
To clarify and define the whether there has any rela-
tion between development of GC progression and
plasma D-dimer, we injected different human GC cell
lines (AGS and MGC80-3) into immunodeficient mice.
After two weeks, it was observed that the D-dimer
levels were gradually elevated in subcutaneous metastasis
(0.75 mg/l ±0.17), intra-peritoneal metastasis (1.38 mg/l ±
0.13) and hematogenous metastasis (1.98 mg/l ± 0.15),
which is higher than control group mice (0.46 mg/l ± 0.05)
(p < 0.001) (Fig. 1a, b). Moreover, the results strongly sup-
ported that the plasma D-dimer were exceptionally
increased in the hematogenous metastasis group
(MGC80-3, 1.98 mg/l ± 0.15) than in PBS treatment group
(0.46 mg/l ± 0.05,p < 0.001) and D-dimer level was also
elevated in hematogenous metastasis group (AGS,
1.73 mg/l ± 0.15) compared with the PBS control group
too (0.46 mg/l ± 0.05) (P < 0.001) (Fig. 1c).
Levels of FIB and FDP in vivo model
Although the development of plasma FDP was consist-
ent with that of plasma D-dimer, it was not as obvious
as the presence of D-dimer (Fig. 2a, b). However, plasma
FIB was decreased in the three tumor-burdened groups,
but no differences were found between the groups
(Fig. 2a, b). Plasma FDP showed a linear association with
the D-dimer level (R2 = 0.628, p < 0.001), and this trend
can be seen in Fig. 2a. However, FIB did not show any
considerable association with the plasma D-dimer level
(Fig. 2c).
Fig. 1 Plasma D-dimer levels in different in vivo metastasis models. a, Different in vivo metastasis models: 1. subcutaneous metastasis, 2. intra-peritoneal
metastasis, 3. hematogenous metastasis and control. b, The plasma D-dimer levels increased gradually in the different in vivo models compared with the
control, hematogenous (3) > intra-peritoneal (2) > subcutaneous (1) > control (p < 0.001). c, The plasma D-dimer levels in the hematogenous metastasis in
vivo model were higher inMGC80-3 GC cell lines and AGS cell lines compared with the control group (p < 0.001). * indicates that the correlation is
significant at the 0.05 level (2-tailed). ** indicates that the correlation is significant at the 0.01 level (2-tailed)
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Patient data
In total, 41 patients with gastric cancer (34 male and 7
female with the age at 40–83 years) were enrolled in this
study. The gastric cancer group enrolled 11 stage III B
and 30 stage IV patients. Among all the patients,14 pa-
tients were defined via histological grade as G1 stage,
that is well differentiated, G2 stage is moderately differen-
tiated, moreover, another 27 patients were classified with
G3, that is poorly differentiated or G4 as undifferentiated.
After clinical multi-departmet-analysis and evaluation, the
following 41 patients with GC with subgroup as: 20 pa-
tients received surgical resection without margins regent,
that is R0 resection, 15 patients received gastric resection
and more than 20 lymph node with microscopic residual
in pathology result (R1 resection) and 6 patients received
palliative resection accompany or not with exploratory
laparotomy. Data before treatments of D-dimer, CEA and
CTCs are listed in Table 1.
Correlations of the D-dimer, CEA & CTCs with other
important factors are recorded and listed (Table 2).
Spearman correlation analysis demonstrate the plasma
D-dimer and CTCs have greatly relationship with meta-
static lymph-node invasion (p = 0.014 & p = 0.021),
whereas the CEA level did not demonstrate any correl-
ation with metastasis (p = 0.315) as shown in Table 2.
The association between D-dimer and CTCs
CTC counts in this study were performed with the Cell-
Search system with specific antibodies: CTC cells was
detected wtih CK (cytokeratins8, 18, and 19) (+) and
DAPI(+) and CD45(−); Leukocyte cells were detects with
CK(−) and DAPI(+) and CD45(−) (Fig. 3a). In this 41 pa-
tients with advanced GC (including 11 stage III B and
30 stage IV patients) 19 of the 41 patients had detect-
able CTCs ≥ 1 (46.3%), 13 of 41 patients had detectable
CTCs ≥ 2 (31.7%), and 10 of the 41 patients had detect-
able CTCs ≥ 3 (24.4%). The result strongly exhibited a
liner relationship between CTCs and D-dimer. (R2 =
0.688, p < 0.001), but not with CEA levels (R2 = 0.002, p
< 0.804) (Fig. 3b, c).
Fig. 2 Plasma FIB and FDP levels in different in vivo metastasis models. a, b, The plasma FDP levels were increased in different in vivo models,
but not to the same extent as the D-dimer levels; The plasma FIB levels in the different in vivo models were decreased in the subcutaneous
model compared with the control, but were not different among the several tumor models. c, In different in vivo models, the plasma D-dimer
level showed a linear relationship with plasma FDP, but not with plasma FIB
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We compared the effectiveness of the plasma D-
dimer, CTC, CEA and metastasis (detected by imaging
tests and/or by the pathology) in the prediction of pa-
tient outcomes. Different levels (high/low) were defined
in the standard of baseline plasma D-dimer amount
(≥1.5 or < 1.5 mg/ml), CTCs (≥2 or <2), and the CEA
level (≥3.4 ng/ml or <3.4 ng/ml) and Metastasis (as de-
tected by imaging tests and/or by the pathology) (positive
or negative) in 29 followed-up advanced GC patients, the
result found that the D-dimer level (p = 0.022) had a
higher accuracy in prognosis prediction than CTCs (p =
0.136), CEA (p = 0.068) and even metastasis (p = 0.602) in
advanced GC patients (Table 3 and Fig. 4a–d).
Discussion
Nowadays, distant metastasis remains poor prognosis
and leads to invalid treatment in cancer patients. It is
widely accepted that activated coagulation, which is
common in malignancy, provides great facile for cancer
metastasis [2, 18–21]. Moreover, in cancer patients, it
usually observed evidence of hemostatic system activa-
tion, which is a well-known phenomenon, and studies in
recent years have shown that cancer and hemostatic sys-
tem exist a bidirectional effect. Potential mechanism of
D-dimer elevation in malignancy might associated with
CTCs Clot (tumor emboli): Following initial tumor cell
arrest in the capillary or bigger vessel of an organ, then
platelets, plasma and other elements are easily clotted
and formed stably adhesion to the cancer cell through
the generation of a thrombus that protects the cancer
cells to proliferation, adhesive and spread via the vascu-
lature. Clots (tumor emboli) participate in the process of
metastasis in several mechanisms including the follow-
ing: the protection for cancer cells from the destruction
of the immune system, blood flow stress, the facilitation
of the attachment of tumor cells to the vessel walls, the
enhancement of extravasation or angiogenesis or the fa-
cilitation of endothelial cell retraction [2, 18–21]. The
individual components of coagulation have been shown
to affect metastasis. Palumbo et al. showed that FIB
Table 1 The basic patient data and median and 25th–75th percentile of plasma D-dimer, CEA levels and CTC positive rate in 41 Gas-
tric Cancer patients
Variable No of case CTC-positive (%) D-dimer CEA
Gender
Male 34 10 (29.41%) 1.10 (0.58–2.35) 2.80 (1.58–19.53)
Female 7 3 (42.85%) 1.30 (0.50–3.30) 4.21 (1.63–19.46)
Age
≤ 61 19 7 (36.84%) 1.30 (0.50–3.50) 2.79 (1.38–19.46)
>61 22 6 (27.27%) 1.05 (0.70–1.77) 3.15 (1.70–10.25)
Histological Grade
G1–G2 14 4 (28.57%) 0.85 (0.48–1.62) 4.27 (2.92–25.30)
G3–G4 27 9 (33.33%) 1.30 (0.70–3.30) 2.25 (1.38–5.46)
TNM Stage
IIIB 11 0 0.50 (0.30–1.10) 4.34 (2.16–19.46)
IV 30 13 1.50 (0.87–3.35) 2.43 (1.58–10.25)
Metastasis
M0 20 3 0.95 (0.50–1.65) 2.60 (1.39–14.59)
M1 16 6 1.10 (0.62–2.12) 2.99 (1.78–39.44)
M2 5 4 7.10 (2.45–26.80) 4.70 (1.56–64.81)
Surgery
R0 20 3 1.00 (0.35–1.65) 2.50 (1.39–4.76)
R1 15 7 1.60 (0.70–3.80) 2.96 (1.63–17.83)
Other 6 2 1.40 (0.80–9.35) 28.11 (2.40–157.25)
M1 means intra-peritoneal metastasis; M2 means visceral metastasis
Table 2 Associations between D-dimer, CEA, CTC and
Clinicopathological Features in Patients with Gastric Cancer
Variable P (CTC) P (D-dimer) P (CEA)
Gender 0.424 0.973 0.721
Age 0.589 0.799 0.119
Histological Grade 0.513 0.235 0.07
TNM Stage 0.012* 0.002** 0.487
Metastasis 0.014* 0.021* 0.315
P indicate that the p-value was analyzed via Spearman Correlation analysis was
employed; *indicates p-value < 0.05 (2-tailed). **indicates p-value < 0.01 (2-tailed)
Diao et al. BMC Cancer  (2017) 17:56 Page 5 of 9
Fig. 3 The images of CTC and leukocyte and relationship among the CTCs and the levels of plasma D-dimer and CEA. a, The images of CTC and
leukocyteB detected by Cellsearch system in this study. b, The number of CTCs showed a linear relationship with the plasma D-dimer levels. c, The
CTCs counts did not showed a linear relationship with the plasma CEA levels
Table 3 Prognostic variables of D-dimer (mg/l), CEA, CTC for overall survival in GC patients
Prognostic Variable No. case (survival rate) Median survival time (m) 95% CI P
D-dimer
≥ 1.5 mg/l 13 (15.4%) 11 6.6–21 0.022*
<1.5 mg/l 16 (43.8%) 19 11.2–26.8
CTC
≥ 2 10 (20.0%) 10 4.8–15.2 0.136
<2 19 (36.8%) 19 11.9–26.0
CEA
≥ 3.4 μg/ml 11 (9.1%) 14 6.7–21.3 0.068
<3.4 μg/ml 18 (44.4%) 19 0.29–37.7
Metastais
Negative 15 (26.7%) 13 9.2–16.8 0.602
Positive 14 (35.7%) 17 10.9–23.1
P indicate that the p-value was analyzed via Kaplan-Meier method; *indicates p-value <0.05 (2-tailed). CI means confidence interval of median survival time
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served as a significant factor for CTCs metastasis ability
[22, 23]. The absence of platelets induced by anti-
platelet agents or special gene modified mice that can
not generate platelets decreased cancer cell metastasis
potential [20, 24]. Metastasis was also reduced by anti-
thrombin treatments, in addition, mice absence of platelet
thrombin receptor also harbor less cancer metastasis [25].
FIB in the other hand, format fibrin and decomposed into
fibrinolysis in some conditions, lead to elevated plasma D-
dimer. In the case of CTCs clot forming, D-dimer usually
increased, and this factor may reflect metastasis of cancer
in bloodstream, as shown at Fig. 5.
In our present study, we first verified that plasma D-
dimer are significantly increased in a metastasis model
in vivo especially in hematogenous metastasis, under-
lying D-dimer increased when CTCs spread into the
vascular, this factor reflect cancer metastasis and might
be an accompaniment for CTCs of GC. Well in addition,
we compared effectiveness of the levels of D-dimer,
CellSearch-CTCs, CEA and Metastasis (as detected by
Fig. 4 The Kaplan-Meier analysis of the survival of patients with gastric cancer. a, The survival rate was lower in patients with D-dimer levels
over 1.5 mg/l (A), but the levels of CEA (b) and CTC (c) and Metastasis (d) diagnosed by imaging did not show any significant difference in
the survival analysis
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imaging tests and/or by the pathology) in the prediction of
patient outcomes and found plasma D-dimer served as a
better outcome predictor comparing to CellSearch-CTCs
detection in cost performance, CEA and metastasis in pa-
tients with advanced GC. What is very interesting, Graph
describing D-dimer and Cell Search-CTCs showed a linear
relationship. This work found D-dimer is an important ac-
companiment of CTCs which could be considered in the
detection of hematogenous metastasis in gastric cancer in
clinical.
Discovery and identification of effective cancer bio-
markers predicting metastasis will be helpfully benefit
for improving strategies of cancer treatment. Histo-
pathological analysis of early stage hematogenous me-
tastases in human frequently reveals the coexistence of
thrombosis, with abundant fibrin deposition, coagula-
tion factors is easily occupied for metastasis detection
in clinical work. In our in vivo experiments, data
showed that there was no markedly differences plasma
FIB levels among different cancer groups. Even FIB is
an essential factor in CTCs survival and metastasis,
however, it is not yet feasible to test for metastasis in a
clinical setting. While, detection plasma level of D-
dimer supply with this advantage in the bottleneck of
insufficient cost performance. FDP includes other de-
generation products of fibrinogen and D-dimer, a linear
association was also detected because affected by D-
dimer. However, it was regret that CTCs counts in mouse
model can not be detected by Cellsearch method because
of the low volume of mouse blood, but in this clinical
study in 41 GC patients, CTCs showed a linear association
with plasma D-dimer (R2 = 0.688, p < 0.001), CTCs, we
thought D-dimer can reflect CTCs number sometimes in
human being, which may be also persuasive.
Cellsearch system can be used in CTCs detection in
whole blood. A study by Khoury discovered an obvious
correlation between CTC positive number and plasma D-
dimer. increases D-dimer levels versus CTC counts are
better suggesting progressive cancer state in 28 prostate
cancer patients [26]. Present study did not find enough
evidence directly support that Cellsearch-CTCs can be
served as a good biomarker of human GC, because CTCs
lack cytokeratin expression or as epithelial-mesenchymal
transition (EMT) exist in cancer cell metastasis. Our
study detected CTCs in 41 advanced GC patients by
CellSearch System, and the result confirmed the linear
relationship between CTCs and D-dimer in GC pa-
tients. We also found that the D-dimer level in the
plasma was able to predict survival, which is more effi-
cient than Cellsearch-CTCs detection, imaging methods
and blood CEA. This finding convinced us that D-dimer
can predict hematogenous metastasis, reflecting a negative
outcome of patients with GC.
Conclusions
In summary, we discussed that D-dimer, coming from
decomposition of fibrin, stably exist in human plasma,
served as an essential accompaniment of CTCs in GC
that is easy to measure and lower in cost, and can be
used in the detection of hematogenous metastasis. This
detection method is of considerable value for routine
test and can remarkably help clinical doctors predict GC
patients outcome.
Fig. 5 The potential mechanism of D-dimer elevation in malignancies. Clots (tumor emboli) participate in the process of metastasis through a
variety of mechanisms including the following: the protection of cancer cells from the destruction of the immune system, or from the physical
stress of blood flow, the facilitation of the attachment of tumor cells to the vessel walls, the enhancement of extravasation or angiogenesis. The
components of the coagulation system including platelets, fibrin, thrombin, plasmin, tissue factor, sFn, and PARs, among others, have been shown
to promote clot formation, which can affect metastasis. Fibrinogen plays a role in the adhesion and survival of circulating tumor cells. Fibrinogen
is actively converted into fibrin and that process of fibrinolysis results in increased D-dimer levels. The plasma D-dimer levels are elevated after
clot formation and may be involved in the promotion of a metastatic phenotype in the bloodstream
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